A Randomized, Double-Blind, Phase 3 Study Evaluating the Safety and Efficacy of Venetoclax in Combination with Azacitidine in Patients Newly Diagnosed with Higher-Risk Myelodysplastic Syndrome (Higher-Risk MDS) Principal Investigator: Dr. Brett Brinker For more information on this trial, read its profile on clinicaltrials.gov here.
Clinical Trial Type: Hematology
AstraZeneca D8227C00001 (ACERTA ESCALADE)
Description: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Acalabrutinib in Combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Subjects ≤65 Years with Previously Untreated Non-Germinal Center Diffuse Large B-Cell Lymphoma Principal Investigator: Dr. Brett Brinker For more information on this trial, read its profile on clinicaltrials.gov here.
MMY3021 (AURIGA)
A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant Principal Investigator: Dr. Erin Pettijohn For more information on this trial, read its profile on clinicaltrials.gov here.
University of Chicago (COBRA)
A Randomized, Open-label Phase 3 Study of Carfilzomib, Lenalidomide, and Dexamethasone Versus Bortezomib, Lenalidomide and Dexamethasone (KRd vs. VRd) in Patients With Newly Diagnosed Multiple Myeloma (COBRA) PI: Dr. Brinker Available at: CHCWM – Muskegon, Holland Cancer Center, Lacks Cancer Center at Saint Mary’s, Lemmen-Holton Cancer Pavilion
Celgene Connect MDS/AML
Seattle Genetics (ECHELON-3)
A Randomized, Double-blind, Placebo-Controlled, Active-Comparator, Multicenter, Phase 3 Study of Brentuximab Vedotin or Placebo in Combination With Lenalidomide and Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) Principal Investigator: Dr. Erin Pettijohn For more information on this trial, read its profile on clinicaltrials.gov here.